Production (Stage)
Arcutis Biotherapeutics, Inc.
ARQT
$13.98
$0.322.34%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 29.17% | 83.72% | 7.21% | 26.28% | 55.83% |
Total Depreciation and Amortization | 774.86% | 18.96% | 270.03% | -9.07% | -1.38% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 4.20% | 20.61% | -3.69% | 13.03% | 5.52% |
Change in Net Operating Assets | -225.01% | -481.27% | 58.56% | 25.48% | 39.57% |
Cash from Operations | 3.87% | 98.67% | 21.13% | 32.14% | 60.67% |
Capital Expenditure | -- | 100.00% | -123.44% | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 143.06% | 156.09% | 86.17% | -169.51% | -126.61% |
Cash from Investing | 140.95% | 156.08% | 86.12% | -169.72% | -126.63% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -99.76% | -97.39% | -54.56% | 36.36% | 161,664.00% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -99.76% | -198.11% | -54.56% | 36.36% | 161,664.00% |
Foreign Exchange rate Adjustments | 105.48% | -444.12% | 230.67% | -388.89% | -40.38% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -117.98% | -233.02% | 2,045.99% | -546.36% | 269.30% |